Literature DB >> 3203524

Properties of permuted-block randomization in clinical trials.

J P Matts1, J M Lachin.   

Abstract

This article describes some of the important statistical properties of the commonly used permuted-block design, also known simply as blocked-randomization. Under a permutation model for statistical tests, proper analyses should employ tests that incorporate the blocking used in the randomization. These include the block-stratified Mantel-Haenszel chi-square test for binary data, the blocked analysis of variance F test, and the blocked nonparametric linear rank test. It is common, however, to ignore the blocking in the analysis. For these tests, it is shown that the size of a test obtained from an analysis incorporating the blocking (say T), versus an analysis ignoring the blocking (say TI), is related to the intrablock correlation coefficient (R) as TI = T(1-R). For blocks of common length 2m, the range of R is from -1/(2m-1) to 1. Thus, if there is a positive intrablock correlation, which is more likely than not for m greater than 1, an analysis ignoring blocking will be unduly conservative. Permutation tests are also presented for the case of stratified analyses within one or more subgroups of patients defined post hoc on the basis of a covariate. This provides a basis for the analysis when responses from some patients are assumed to be missing-at-random. An alternative strategy that requires no assumptions is to perform the analysis using only the subset of complete blocks in which no observations are missing. The Blackwell-Hodges model is used to assess the potential for selection bias induced by investigator attempts to guess which treatment is more likely to be assigned to each incoming patient. In an unmasked trial, the permuted-block design provides substantial potential for selection bias in the comparison of treatments due to the predictability of the assignments that is induced by the requirement of balance within blocks. Further, this bias is not eliminated by the use of random block sizes. We also modify the Blackwell-Hodges model to allow for selection bias only when the investigator is able to discern the next assignment with certainty. This type of bias is reduced by the use of random block sizes and is eliminated only if the possible block sizes are unknown to the investigators. Finally, the Efron model for accidental bias is used to assess the potential for bias in the estimation of treatment effects due to covariate imbalances. For the permuted-block design, the variance of this bias approaches that of complete randomization as the half-block length m----infinity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1988        PMID: 3203524     DOI: 10.1016/0197-2456(88)90047-5

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  75 in total

1.  Design and conduct of the CALERIE study: comprehensive assessment of the long-term effects of reducing intake of energy.

Authors:  James Rochon; Connie W Bales; Eric Ravussin; Leanne M Redman; John O Holloszy; Susan B Racette; Susan B Roberts; Sai Krupa Das; Sergei Romashkan; Katherine M Galan; Evan C Hadley; William E Kraus
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-10-05       Impact factor: 6.053

2.  Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery.

Authors:  Elena Losina; James Wright; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2012-03-21       Impact factor: 5.284

3.  A simplified formula for quantification of the probability of deterministic assignments in permuted block randomization.

Authors:  Wenle Zhao; Yanqiu Weng
Journal:  J Stat Plan Inference       Date:  2011-01-01       Impact factor: 1.111

4.  Environmental intervention for house dust mite control in childhood bronchial asthma.

Authors:  Engy M El-Ghitany; Magda M Abd El-Salam
Journal:  Environ Health Prev Med       Date:  2012-09       Impact factor: 3.674

5.  Reproductive health choices for young adults with sickle cell disease or trait: randomized controlled trial immediate posttest effects.

Authors:  Diana J Wilkie; Agatha M Gallo; Yingwei Yao; Robert E Molokie; Christine Stahl; Patricia E Hershberger; Zhongsheng Zhao; Marie L Suarez; Robert J Labotka; Bonnye Johnson; Rigo Angulo; Veronica Angulo; Jesus Carrasco; David Shuey; Stephanie Pelligra; Edward Wang; Dennie T Rogers; Alexis A Thompson
Journal:  Nurs Res       Date:  2013 Sep-Oct       Impact factor: 2.381

6.  Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes over Two Years.

Authors:  Agatha M Gallo; Diana J Wilkie; Yingwei Yao; Robert E Molokie; Christiane Stahl; Patricia E Hershberger; Zhongsheng Zhao; Marie L Suarez; Bonnye Johnson; Rigoberto Angulo; Jesus Carrasco; Veronica Angulo; Alexis A Thompson
Journal:  J Genet Couns       Date:  2015-08-28       Impact factor: 2.537

7.  Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial.

Authors:  F Perry Wilson; Michael Shashaty; Jeffrey Testani; Iram Aqeel; Yuliya Borovskiy; Susan S Ellenberg; Harold I Feldman; Hilda Fernandez; Yevgeniy Gitelman; Jennie Lin; Dan Negoianu; Chirag R Parikh; Peter P Reese; Richard Urbani; Barry Fuchs
Journal:  Lancet       Date:  2015-02-26       Impact factor: 79.321

8.  Vaccine testing. Ebola and beyond.

Authors:  Marc Lipsitch; Nir Eyal; M Elizabeth Halloran; Miguel A Hernán; Ira M Longini; Eli N Perencevich; Rebecca F Grais
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

Review 9.  Is restricted randomisation necessary?

Authors:  Catherine E Hewitt; David J Torgerson
Journal:  BMJ       Date:  2006-06-24

10.  The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, controlled pilot study.

Authors:  P Tranos; R Scott; H Zambarakji; H Zambarajki; W Ayliffe; C Pavesio; D G Charteris
Journal:  Br J Ophthalmol       Date:  2006-05-24       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.